Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975117 | 0.89 | ALDH1A1 (0.68) | ALDH1A1MAPTCTSDMEN1KMT2A | |
| SCHEMBL8674784 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAHSP90AA1ATM | |
| SCHEMBL8674787 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAHSP90AA1ATM | |
| SCHEMBL1681866 | 0.80 | PRNP (0.53) | ALDH1A1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL29470997 | 0.80 | PRNP (0.53) | ALDH1A1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL11282500 | 0.80 | KCNMA1 (0.59) | ALDH1A1MAPTLMNACTSDMEN1 | |
| SCHEMBL5705801 | 0.80 | TSHR (0.59) | ALDH1A1MAPTLMNACTSDMEN1 | |
| SCHEMBL11300388 | 0.79 | MEN1 (0.58) | ALDH1A1MAPTLMNACTSDMEN1 | |
| SCHEMBL30201466 | 0.79 | MEN1 (0.58) | ALDH1A1MAPTLMNACTSDMEN1 | |
| SCHEMBL8575758 | 0.79 | CTSD (0.57) | ALDH1A1MAPTCTSDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0902018-B1 | 2-(Arylphenyl)amino-imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7141584-B2 | guanidine derivatives containing phenyl and imidazole rings; useful for treating pain conditions from a wide variety of causes such as cancer, trauma, surgery, inflammation etc. | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2004-06-24 | — | — | US | disclosed |
| US-6693200-B2 | IP RECEPTOR ANTAGONISTS; ANTIINFLAMMATORIES AND ANALGESICS | SYNTEX (U.S.A.) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6596876-B2 | Prostaglandin I2 inhibitors | SYNTEX (U.S.A.) LLC | 2003-07-22 | — | — | US | disclosed |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-4018788-A | 6-(O-Halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepine | THE UPJOHN COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | ALDH1A1 873/4885MAPT 4794/4885LMNA 4109/4885 |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, GRK2, TBXA2R | ALDH1A1 2564/4885MAPT 4533/4885LMNA 4755/4885 |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, TBXA2R, GRK2 | ALDH1A1 2682/4885MAPT 4459/4885LMNA 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.